<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR17">
 <label>17.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Connick</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Kolappan</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Crawley</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Webber</surname>
    <given-names>DJ</given-names>
   </name>
   <name>
    <surname>Patani</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Michell</surname>
    <given-names>AW</given-names>
   </name>
   <name>
    <surname>Du</surname>
    <given-names>MQ</given-names>
   </name>
   <name>
    <surname>Luan</surname>
    <given-names>SL</given-names>
   </name>
   <name>
    <surname>Altmann</surname>
    <given-names>DR</given-names>
   </name>
   <name>
    <surname>Thompson</surname>
    <given-names>AJ</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study</article-title>
  <source>Lancet Neurol</source>
  <year>2012</year>
  <volume>11</volume>
  <fpage>150</fpage>
  <lpage>156</lpage>
  <pub-id pub-id-type="doi">10.1016/S1474-4422(11)70305-2</pub-id>
  <?supplied-pmid 22236384?>
  <pub-id pub-id-type="pmid">22236384</pub-id>
 </element-citation>
</ref>
